Clinicians' Corner in Dyslipidemia

Slides:



Advertisements
Similar presentations
Statin Myopathy (AHA/ACC/NHLBI)
Advertisements

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Optimizing Statin Therapy
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Advances in Dyslipidemia: What Have We Learned From ACC 2017
What Do We Know About LDL-C?
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
Statin Class in Session
PCSK9 Inhibitors and Cardiovascular Outcomes
% decrease in LDL-C at 24 weeks from baseline
% decrease in LDL-C at 24 weeks from baseline
ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Monoclonal Antibodies in CVD: What Does the Future Hold?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
Practical Strategies for Getting Patients With Diabetes to Lipid Goal
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
PCSK9 Inhibitors and Statin Intolerance
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Clinicians' Corner in Dyslipidemia

Multiple Challenges With Statin Selection

Statin-Associated Muscle Symptoms vs Statin Intolerance

GAUSS 3 Study Design

GAUSS 3 Study Implications

Nonstatin Therapy for Adjunct LDL-Lowering

PCSK9 Inhibitors Dosing and Administration

PCSK9 Inhibitors Indications

FOURIER Trial Design

Summary of Effects of PCSK9I Evolocumab

FOURIER Trial: Relationship Between Achieved LDL-c Levels at One Month to Measures of Benefit

FOURIER Safety

Nonstatin Recommendations From Treatment Guidelines

Guideline Recommendations for Additional LDL-C Reduction With Nonstatin Therapy

When to Consider Nonstatin Therapy

Alirocumab ODYSSEY Outcomes Trial

Alirocumab ODYSSEY Outcomes Trial Results

Navigating the Prior Authorization Process Clinical Pearls

Statin-Associated Myopathy Risk Factors

Successful Statin Reintroduction

Management of Statin-Related AEs

Sample Uniform Prior Authorization and Appeals Letters

Improving PCSK9 Inhibitor Approval Rates

Real-World Experience With FH and PCSK9 Inhibitors

Navigating the Prior Authorization Process With the Patient

Clinical Management of the Patient With Dyslipidemia

Specialty Pharmacy PCSK9 Inhibitor Access

Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

Conclusion

Abbreviations

Abbreviations (cont)